Impressively, combination treatment with PRMT5 and ATR inhibitors also showed more potent cytotoxicity on ATM-deficient MCL cells than those treated with either inhibitor alone, as indicated by the synergistic cytotoxic effects (Fig. 6b and Supplementary Fig. S5a). This evidence concerns the gene ATR and mantle cell lymphoma.